A pharmacy counter in Los Angeles is adorned with a box of Ozempic, a diabetes drug. This image, captured on April 17, 2023, showcases the significance of weight-loss drugs in the United States. However, a recent analysis by KFF, a health policy organization, reveals that these blockbuster drugs are priced substantially higher in the U.S. compared to other large and affluent nations.
The exorbitant cost of weight-loss drugs has become a major concern for U.S. health insurers, leading many to remove these medications from their plans. With an average monthly cost of around $1,000, these drugs, known as GLP-1 agonists, create a financial burden for insurers. Unfortunately, the individuals who would benefit from these treatments the most—over 100 million obese American adults—cannot afford to pay out of pocket.
The KFF analysis focused on comparing list prices, which are the prices set by drugmakers before insurance or any discounts are applied. Interestingly, various countries take different approaches when negotiating with drugmakers. Some nations, such as Japan, directly negotiate lower list prices with drugmakers like Novo Nordisk. In contrast, the U.S. does not engage in such negotiations, resulting in significantly higher list prices.
For example, Novo Nordisk’s diabetes drug Ozempic, used off-label for weight loss, has a list price of $936 in the U.S. In comparison, the same drug costs only $168 in Japan, making it five times more expensive in the United States. The price difference is even more drastic in other countries, where Ozempic is priced at $103 in Germany, $96 in Sweden, and $83 in France.
Similarly, Novo Nordisk’s Wegovy, which shares the same active ingredient as Ozempic and is specifically approved for weight loss, has a list price exceeding $1,300 in the U.S. In contrast, it is priced at just $328 in Germany. Eli Lilly’s diabetes drug, Mounjaro, also used off-label for weight loss, follows a similar trend. Its list price in the U.S. is $1,023, while it is only $319 in Japan and $444 in the Netherlands.
The impact of these list prices and the limited insurance coverage for weight-loss drugs in the U.S. becomes evident in the accessibility of these medications. A recent KFF survey revealed that nearly half of all U.S. adults show interest in taking prescription weight-loss drugs. However, this interest drops to a mere 16% if the medication is not covered by insurance.
Furthermore, the survey highlights that 80% of adults believe insurance companies should cover the cost of weight-loss drugs for overweight or obese individuals, and 50% believe insurers should cover the cost for anyone seeking to lose weight. These findings emphasize the importance of insurance coverage in facilitating access to these medications.
Last week, Novo Nordisk released new trial data showcasing the potential health benefits of Wegovy. The trial demonstrated a 20% reduction in the risk of serious heart problems and heart-related death in overweight or obese patients with established cardiovascular disease. These results suggest that obesity drugs like Wegovy offer significant benefits beyond weight loss. However, insurance organizations have expressed the need for additional data before expanding coverage for these medications.
In conclusion, the analysis by KFF sheds light on the stark disparity in pricing for weight-loss drugs between the U.S. and other countries. The high cost of these medications and limited insurance coverage hinder accessibility for obese individuals. Efforts to address this issue should focus on negotiating lower list prices and expanding insurance coverage, considering the potential health benefits these drugs offer.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
